Good day, and welcome to the Elanco Animal Health Q1 2026 Earnings Call. Please note, this call is being recorded. I would now like to turn the call over to Tiffany Kanaga, Vice President of Investor Relations and ESG. Please go ahead.

Good morning. Thank you for joining us for Elanco Animal Health's First Quarter 2026 Earnings Call. I'm Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer; Bob VanHimbergen, our Chief Financial Officer; and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today's earnings press release as well as in our latest Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements. Our remarks today will focus on our non-GAAP financial measures. Reconciliations of these non-GAAP measures are included in the appendix of today's slides and in the earnings press release. References to organic performance exclude certain royalty and milestone rights that were sold to a third party in May 2025. After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeff.

Thanks, Tiffany. Good morning, everyone. Elanco's first quarter represents growing strength, momentum and value. The company's solid first quarter results and raised full year guidance demonstrate continued progress on our priorities of growth, innovation and cash. As highlighted on Slide 4, we delivered 10% organic constant currency revenue growth in the quarter, outperforming the high end of guidance for revenue, adjusted EBITDA and adjusted EPS. This high-quality performance was driven by both price and volume, with growth across all major geographies and all species. Thank you to the entire Elanco team for the execution, for high levels of engagement and unified approach that have created a sustained, consistent delivery across the company. Elanco is in a position of strength with a base business that grew in Q1 and a basket of significant innovation, all within a durable animal health industry. Our momentum in each of our four businesses is evident in market share gains across our global portfolio. We drove share gains across all of our U.S. pet health major categories: parasiticides, osteoarthritis pain, dermatology and vaccines. Elanco's leading share growth in the largest categories, parasiticides and dermatology, with accelerating gains for Zenrelia and Credelio Quattro. Internationally, both Zenrelia and AdTab continued their growth trajectories and captured market share. We also bolstered our leadership in U.S. farm animal and achieved strong growth in international farm animal, particularly in poultry and ruminants. Our diverse basket of significant innovation is a key driver for this global momentum. After delivering $287 million of first quarter revenue from our innovation products, we are raising our full year innovation target to $1.2 billion. Our Big 6 products are performing extremely well, and they are providing portfolio benefits that supported our base business growth in Q1. Robust top line and adjusted EBITDA growth combined to enable continued deleveraging in the quarter. We are improving our net leverage target for year-end to 3.0 to 3.2x from the previous guidance of 3.1x to 3.3x. With our solid start to the year and accelerating trends into March and April, we are well positioned to raise our top and bottom line outlook. For the full year, we now expect organic constant currency growth of 5% to 7%. Adjusted EBITDA of $975 million to $1.005 billion, representing 10% at the midpoint, and adjusted EPS of $1.03 to $1.09, representing 13% growth at the midpoint. This guidance continues our prudent, balanced approach in a dynamic macro environment. Our confidence comes from the consistent outperformance of our diverse basket of innovation, a growing base business in Q1 and the mega trends supporting durable growth in today's global animal health industry. Looking more closely at the first quarter revenue performance on Slide 5, we break down the 10% underlying organic constant currency revenue growth. U.S. Pet Health achieved 6% growth despite winter storms impacting January and February in the vet clinic. We saw a sharp recovery in March to 8% growth with April even better. Both months were ahead of expectations and demonstrate our underlying strength. Zenrelia posted its best quarter yet, leading our Q1 growth in the clinic and far exceeding our plans. Also robust Credelio Quattro demand with accelerating market share gains more than offset the anticipated headwind from last year's typical launch dynamics of initial stocking. Both brands exited the quarter with strong momentum in March and extending into April. We are well positioned for active dermatology and parasiticide seasons with tick bites sending Americans to the emergency room at the highest rate in nearly a decade, according to April CDC data. We expect one of the most robust parasiticide seasons in a long time. In our U.S. retail OTC business, Q1 saw high single-digit consumption growth in a low growth market, reflecting strong trends for our products and Costco and Dollar General as new customers. These two new retailers were meaningful additions to our business as flagged at the December Investor Day and should also contribute to growth in upcoming quarters after initial stocking. Both Seresto and the Advantage family saw double-digit dispensing growth at our top retailers. Additionally, Zenrelia and Quattro are growing nicely at retail. We continue to expand our retail market leadership and competitive advantage with what we believe is the broadest access to pet owners in the industry. Overall, our U.S. pet health business is demonstrating solid fundamentals with our basket of innovation driving industry-leading growth. We are confident in an expected acceleration for the business to high single-digit to low double-digit growth in the back half of the year as our new products continue to gain share. Moving to international pet health. We delivered 9% organic constant currency revenue growth, driven by Zenrelia, AdTab and Credelio. Zenrelia is rapidly capturing share in the $800 million international dermatology market with accelerating gains in key markets. U.S. Farm Animal was up 15% with good growth across all species and product categories. Our results demonstrate the power of innovation and a diverse portfolio and a favorable macroeconomic backdrop. Finally, international Farm Animal was up 13% in organic constant currency, also achieving growth across all species. The quarter benefited from customer-driven accelerated shipments primarily to the Middle East contributing 1 percentage point of growth for the total company. Turning now to Slide 6. We delivered $287 million of innovation revenue in the first quarter. With a strong sales trajectory of the Big 6 driven by our no-regret launch approach, we are again raising our innovation guidance for 2026 by $50 million to $1.2 billion. The Big 6 are well positioned to drive sustainable growth over the coming years as we continue to expect this group to double in revenue from 2025 to 2028 on top of a stable base. Let's further discuss the progress of our major innovation products on Slide 7, starting with Zenrelia, the single largest brand driving Elanco's 10% growth. Zenrelia reached blockbuster status on a trailing four-quarter basis with a growth trajectory well exceeding our expectations even since the late February earnings call. We are in a stronger position with momentum accelerating in the U.S. and in our international business and growing recognition of the strong efficacy profile. We see potential for Zenrelia to be a blockbuster in both the U.S. and international as we grow the $2.1 billion global dermatology market and continue to take share. As we enter the derm season, we see Zenrelia as the leading dermatology market share taker with demonstrated strong efficacy in the JAK1 category. March was Zenrelia's largest month yet with U.S. vet clinic sell-in 30% larger than any other month to date. We're now at over 16,000 U.S. vet clinics or over 50% of the total, and the reorder rate is over 80%. We've added 4,300 new purchasers since the September label improvement and veterinarians are moving it to first-line treatment as they gain experience and see how this special product works. We expect continued momentum entering the allergy season with those cases representing about one third of the patient population. On the U.S. label, we continue to have constructive dialogue with the FDA regarding our previously submitted data. The FDA has requested additional data and a new study is already underway. Given Zenrelia's success to date that is well beyond our plans, we now have greater expectations for the potential of this product with additional label improvement in the U.S. representing only further possible upside. Our guidance has always conservatively assumed no incremental change to the U.S. label. Building on this success outside the U.S., Zenrelia has posted an excellent quarter across key geographies. A great potential leading indicator example is the first market for Zenrelia, Brazil. Zenrelia has reached over 50% JAK market share in Brazil, becoming the market leader after just one year and achieving this coming through the Southern Hemisphere derm season. In Japan, it's over 35%. Traction continues to rapidly build also in Europe with JAK market share in the high teens to over 30% in key European markets, again outperforming the competitive entrant. Our EU head-to-head study has resonated well with veterinarians, and we're the only player providing this competitive data. With the recent launches, Zenrelia is now in 45 countries and our international labels are all without restrictions. Zenrelia's efficacy is a clear differentiator and game changer, addressing the top reason dogs go to the vet and satisfying an unmet need for pet owners. Over 2 million dogs have now been treated with Zenrelia, and we're just getting started. We are increasing manufacturing capacity and moving production now to 24/7 to keep up with sharply rising global demand and going into what we expect to be a robust derm season. Moving to our second derm product, Befrena. Our phased launch approach is on track with product already shipped to early experience influencers and in use. We expect to officially launch Befrena this quarter and have orders in hand as vets are eager for this new solution. Remember that a phased launch is very typical for a monoclonal antibody or mAb products as we scale our bioreactors with anticipated manufacturing ramp-up. We're excited for Befrena as a potential blockbuster with positive differentiation on convenience, value and efficacy. It's recommended at a dosing interval of 6 to 8 weeks post treatment versus 4 to 8 weeks for the current market competitor. When we shared a close proxy of the label to over 350 veterinarians, 83% responded they're likely to use Befrena, especially in seasonal cases. And importantly, Befrena is complementary to our broader portfolio, creating a more comprehensive offering to veterinarians. Last week, we hosted over 300 veterinarians at our headquarters as part of the North American Veterinary Dermatology Forum. Anecdotal feedback from early experienced KOLs was positive on the efficacy of Befrena. Next, on Credelio Quattro. We are very pleased by our accelerating pace of dollar share gains in broad spectrum dispensing sales from U.S. clinics. Quattro's market share is up 3 points since Q4 and exceeding our expectations. Most importantly, in the clinics that carry Quattro, which is now over 40% of the U.S. clinic base today, our share increased 13 points in Q1, reaching 53%. Simply put, the clinics carrying Quattro are using it more than half of the time for any broad spectrum application. These accelerating gains one year after launch demonstrates strong demand and growing interest from veterinarians and pet owners who increasingly agree that Quattro is best medicine with its four dimensions of differentiation. The product's success also reflects our strategic DTC investments, enhanced sales team and distribution partnerships, which combine to fuel a growth trajectory more like a first-to-market product. We will continue to fund our data-driven high ROI investments in the brand. Like Zenrelia, sales for Quattro accelerated during the quarter. March has been the product's largest month ever, creating strong momentum into the parasiticide season. We've added over 2,500 new clinics year-to-date through April and counting. And yet there remains ample room for Quattro to continue to grow and take share in the $1.5 billion U.S. broad-spectrum parasiticide market. An important leading indicator is the Kinetics Puppy Index, where Quattro ranks highest versus other broad-spectrum andectose products and grew versus Q4. Outside the U.S., Quattro has made its debut in the $750 million international market, which is growing double digits. In April, the product launched in Australia and gained approval in Canada. The EU, the U.K. and Japan are next as we look to rapidly globalize sales. We expect the global Credelio family to eventually become the largest product family in Elanco's history. Finally, our OTC parasiticide AdTab has continued its robust growth trajectory with sales once again up more than 50%. AdTab is the fastest-growing brand in the $600 million OTC ectoparasiticide category in Europe, further strengthening its market leadership in Q1. Moving to Farm Animal. Fifty-five percent of U.S. cattle feed yards are now using Experior. Overall, we expect Experior to continue to grow and drive meaningful portfolio benefits including geographic expansion as another long-term growth driver with recent expansion into Mexico. But we expect a moderating trajectory for this blockbuster with more challenging comparisons ahead. Lastly, on Bovaer, we continue to see demand from CPG companies supporting relatively consistent demand. We're investing in long-term initiatives to enhance the product value and demonstrate user flexibility. More near term, we expect growth at a measured pace as we build on Bovaer's value proposition. Moving to Slide 8. We provide recent highlights across the three parts of our consistent IPP strategy: innovation, portfolio and productivity. Our innovation engine continues to make great progress with further globalization of our Big 6 innovations resulting in recent approvals for Zenrelia in LatAm countries and Eastern Europe, Credelio Quattro in Canada and Australia and new submissions, including the Befrena dossier in Canada. The next wave of innovation in the portfolio further expanded and progressed in line with our plans, and we are clearly tracking towards five to six blockbuster potential approvals expected through 2031. Finally, Ellen and her team have further strengthened the innovation pipeline with new additions coming from our internal discovery teams while advancing key clinical programs, enabling us to clearly see our vision of a consistent flow of high-impact product innovations. Today, the Big 6 are driving broad-based growth across our portfolio and share gains across all quadrants. These launches are powering growth in U.S. corporate accounts, up 12% in Q1 versus the same quarter last year. They've enabled growth for our base business in the quarter, and we are seeing gains from pricing up 2% in Q1 and on track for full year acceleration from 2025. We implemented our largest price increase in five years to U.S. vet clinics, reflecting our latest innovation and the value of our portfolio for customers. Finally, we continue to pay down debt and strengthen our balance sheet. At 3.5x net leverage in Q1, we have a clear path to the under 3x landmark in 2027. Our December strategic restructuring has further streamlined our organization with expansion of R&D in our Indianapolis headquarters, and as Bob will detail momentarily, our company-wide productivity initiative, Elanco Ascend, is on track to drive meaningful efficiencies and margin enhancement starting in 2026. With that, I'll pass it to Bob to provide more on our first quarter results and financial guidance.

Thank you, Jeff, and good morning, everyone. Today, I will focus my comments on our first quarter adjusted measures, so please refer to today's earnings press release for a detailed description of the year-over-year changes in our reported results. Starting on Slide 10. We delivered $1.371 billion of revenue, representing an increase of 15% on a reported basis. Organic constant currency growth was 10% compared to the first quarter of 2025, with 2% from price and 8% from volume. Slide 11 provides revenue by the four quadrants of our business. Total Pet Health revenue increased 7% in constant currency. In the U.S., we achieved 6% growth with broad-based strength across all channels. Key drivers were Zenrelia, Credelio Quattro and our over-the-counter retail parasiticides business. Outside the U.S., our Pet Health business grew 9% in constant currency, driven by sales momentum of our innovation portfolio, including Zenrelia, AdTab and Credelio family products. Globally, our Farm Animal business achieved 13% growth in organic constant currency growing across all species. The U.S. Farm Animal business delivered 15% growth with contributions across all product categories, driven by cattle and poultry. While we are extremely pleased with the outsized performance in the quarter, we do expect growth to normalize to levels consistent with our long-term algorithm. Outside the U.S., our Farm Animal business contributed 13% in organic constant currency growth with poultry and ruminants the major contributors. We estimate that the favorable timing of customer purchases in the Middle East this year contributed 1 percentage point of growth for the total company. Continuing down the income statement on Slide 12. Adjusted gross margin was 57%, a decrease of 40 basis points. As a reminder, we anticipated a year-over-year decline in the quarter due to pressures from inflation and the flow-through of inventory costs. Gross margin performance was also impacted by product mix, with strong Farm Animal growth, partly offset by benefits from both price and volume. Looking ahead, we continue to expect meaningful gross margin expansion in the second half of the year as we move past inventory cost headwinds and with mix benefits from expected acceleration in our U.S. Pet Health business. Operating expenses increased 6% year-over-year in constant currency, driven by planned investments supporting our product launches, continued R&D investments and compensation expense. Interest expense for the quarter totaled $43 million, in line with our expectations. On Slide 13, you'll see an adjusted EBITDA year-over-year comparison for the quarter. Adjusted EBITDA was $334 million, an increase of $58 million or 21%. Adjusted EPS was $0.40, an 8% increase year-over-year. As a reminder, adjusted EPS was impacted by lapping favorable one-time tax benefits in the prior year. On Slide 14, we provide an update on our cash and debt balances. We ended the quarter with net debt of $3.3 billion and a net leverage ratio of 3.5x. Debt paydown remains our primary use of free cash flow with a long-term target ratio of 2 to 2.5x. We expect to reach below 3x next year, giving us greater capital allocation flexibility. In the meantime, we continue to evaluate disciplined bolt-on M&A. I'd like to recognize the closing of our AHV International acquisition on April 30, and welcome our new colleagues. AHV expands our share of voice in dairy, and we are excited about this platform for farm animal innovation. Now let's move to our financial guidance, starting on Slide 16. Our first quarter overperformance allows us to raise our full year expectations and continue to invest in our innovation products. We now expect to deliver organic constant currency revenue growth of 5% to 7% versus our previous outlook of 4% to 6%. We are increasing our expected reported revenue range to be between $5.01 billion and $5.085 billion. This includes an expected $60 million year-over-year tailwind from the favorable impact of foreign exchange rates, the majority of which was captured in our first quarter results. Slide 17 provides year-over-year bridges for 2026 adjusted EBITDA and adjusted EPS, and Slide 24 in the appendix provides additional assumptions to help support your modeling efforts. We are raising adjusted EBITDA guidance by $20 million. The increase reflects our $34 million outperformance in Q1, partly offset by approximately $9 million of incremental investment in our innovative launches and previously mentioned timing of international farm animal sales. For adjusted EPS, we are raising our guidance by $0.03, bringing the new range to $1.03 to $1.09. We have also updated our cash and balance sheet expectations for 2026 and now anticipate end of year net leverage of 3x to 3.2x. We continue to take a balanced and prudent approach to our guidance, considering a number of potential scenarios. On Slide 18, we list drivers that could influence our results within the guided ranges. We remain disciplined in monitoring external headwinds, specifically, heightened competitive pressures, including generics, and consumer level economic shifts. These could move results toward the lower end of our expectations. We also continue to invest incremental dollars to support the launch of our innovation products, driving our market share gains and sustainable growth. Alternatively, the continued acceleration in our innovation pipeline, underlying strength from a growing base business and our ability to leverage our diverse portfolio could drive results towards the high end of our expectations. A favorable macro environment and rapid progress in Elanco Ascend could provide important tailwinds. In conclusion, we see a stronger set of opportunities and momentum in the business, outweighing potential headwinds, resulting in the balanced guidance raise. Now let me take a moment to offer an update on Elanco Ascend. We are seeing significant engagement across the organization as we execute initiatives to optimize our cost structure and drive operational efficiencies. We continue to expect the projected Ascend savings detailed during our December Investor Day. As a reminder, 75% of our benefit from Ascend will be in gross margin, but the near-term benefits are more in G&A, driven by our previously announced restructuring. With more than 5,000 projects logged to date from large-scale transformations to smaller localized improvements, Ascend is becoming deeply embedded in our operational discipline. Additionally, Elanco Ascend is integrating automation and AI across our entire value chain to accelerate our innovation pipeline, enhance manufacturing quality and drive sales through deeper data-driven customer insights. Our comprehensive AI agenda also includes leveraging AI-driven automation to transform legacy processes as part of Ascend. For example, we recently implemented an automated sales order tool that modernizes the order-to-cash process. This initiative enhances fulfillment accuracy and accelerates order cycles leading to improved cash flow visibility and lower operational costs. When you combine our focus on operational excellence and productivity with the continued scaling of our margin-accretive innovation portfolio, we see a clear path for sustainable margin expansion over the long term. Now moving to our second quarter guidance presented on Slide 19. On a reported basis, we expect $1.3 billion to $1.325 billion in revenue, representing organic constant currency revenue growth of 4% to 6%. Growth is impacted by lapping Q2 2025 pretariff buying primarily in China, by accelerated shipments to the Middle East in Q1 of this year and by Farm Animal normalization against more challenging comparisons. The year-over-year increase in operating expenses, primarily related to launch investments, is expected to be approximately 8% in constant currency. As a result, we anticipate adjusted EBITDA of $240 million to $260 million, and adjusted EPS of $0.25 to $0.28. Finally, on Slide 20, we outline our expectations for a meaningful acceleration in our U.S. Pet Health business in the second half of the year. As Jeff highlighted, we saw a sharp recovery in March to 8% growth and even better April, demonstrating our underlying strength. We are confident in our expectations for high single-digit to low double-digit growth in the back half of the year, reflecting continued momentum for Zenrelia and Credelio Quattro and contributions from our Befrena launch. Additionally, our comprehensive portfolio is driving significant corporate account growth. I'd also highlight, our assumptions are not contingent on improvement in vet visit volumes. For the full year, we expect the U.S. Pet Health business to achieve at least high single-digit revenue growth, once again meeting the industry. Now I'll hand it back to Jeff for closing comments.

Thanks, Bob. As we accelerate into 2026, our innovation, portfolio and productivity strategy is working. Elanco is a different company today, well positioned to lead growth in animal health through consistent execution of our strategic priorities: growth, innovation and cash. The base business grew this quarter, while the launch of our Big 6 innovation portfolio builds momentum. Elanco will stay disciplined and focused while anchored on the belief that we are about delivering that promise. We are now advancing our next wave pipeline, targeting five to six new blockbusters by 2031 and unlocking more than $2 billion in unrealized peak sales potential. Through Elanco Ascend, we expect to drive meaningful margin expansion and operational efficiency beginning this year, aiming to deliver more than $1 billion in free cash flow through 2028 and reduce net leverage below 3x by 2027, all of this on top of sustainable megatrends in pets and protein that make animal health a durable, resilient industry and one of the most compelling long-term growth sectors. Elanco is confident in the animal health industry in both 2026 and into the longer-term future. These tailwinds are expected to extend animal health's mid-single-digit growth, adding an estimated $20 billion in industry value over the next decade. Last quarter, I highlighted the robust protein trends for our Farm Animal segment. Specific to pets, I would point to my recent shared table podcast episode with Jay Mazelsky from IDEXX and J. Price from Mission Pet Health. The pet opportunity is significant. Diagnostics are completed on just 20% of pets today. We see only the surface of the true disease spectrum that exists. And as we expand what we detect, AI accelerates what we can learn and a generation of middle-aged pandemic pets enter their highest care years, the pie is growing. The leaders who focus on delivering value to the pet, the owner and the veterinarian to meet this increasing expectation of care will be the ones who grow with it and beyond. I especially want to thank the Elanco team for their commitment to serving customers and continuing to push boundaries to exceed their expectations. Today, strong results and raised outlook for 2026 were made possible through our team's dedication building on more than 70 years of transforming animal health to create long-term value for customers, communities and our shareholders. With that, I'll turn it over to Tiffany to moderate the Q&A.

Thanks, Jeff. We'd like to take questions from as many callers as possible, so we ask that you limit yourself to one question and one follow-up. Operator, please provide the instructions for the Q&A session, and then we'll take the first caller.

Our first question comes from John Block with Stifel.

I'll start. The U.S. Pet Health result in the quarter was up 6%. I'm guessing it was probably a bit lower if we normalize for advantage sales, call it into the new doors. So Jeff, can you talk about what held back the U.S. Pet Health in the earlier part of the quarter, and more importantly, the main drivers to the accelerating assumption? I know there's some good color on Page 20, which I think is very helpful. But any additional feedback would be great. I think that is a focal point for investors here in the near term.

Yes. Thank you, John. Look, we had, like the whole industry, a cooler January and February, but we saw a really nice rebound and all the lead indicators on our new products were extremely strong. So an 8% jump back in March, even stronger in April. And as we look at the forecast with Bob and his team for the rest of the year, and as highlighted on that slide, we see Zenrelia — what a quarter for Zenrelia. It was the number one brand for our company and a major growth driver, and we'll talk more about that, but Zenrelia was a major contributor as well as Quattro. Then we've got the Befrena launch, we've got a step-up in price, and all of this, we believe, on the existing industry backdrop. You mentioned retail. Retail had an extremely strong quarter. The strategy is working. If you look at retail, it was AdTab internationally, but in the U.S., it's bringing an advantaged collar, adding distribution points with a value store in Dollar General all the way to a box store. Today, we're taking share. We're adding double-digit growth to these major key retailers. So the omnichannel is working. We see a nice step up the rest of the year. That's why we wanted to be clear and it comes with a lot of confidence with a March and April trajectory change.

That's great color. And then the second question, it seems like you're talking more openly about these corporate accounts, and it seems like that also has a role in the acceleration. So I'm just curious, are these commitments from corporates, call it, for a first time? Are they competitive wins? And also, when we think about these corporate deals, is it broad-based? In other words, are we talking Credelio Quattro, Zenrelia, Befrena upon launch? Maybe you can provide some details there.

Yes. Corporate accounts — we were very under-indexed. We shared in the last quarter how the number of corporate accounts were growing that weren't growing last year. We saw a 12% step-up, so double the growth rate in corporate accounts. It all comes back to a winning portfolio. When you start to see the uptake — over half the clinics in the U.S. using Zenrelia, 40% with Quattro — and you look at best medicine with Quattro demand for Zenrelia, if you're a corporate account and you don't have this and you've got clients coming and asking, there is more of a pull than a push that's happening with corporate accounts. Bob and his team, Chris Bertelle and Matt Hudson Piller and the team, have done a very nice job of making sure though it is value-based. We are not going places where price would be impacted negatively with corporate accounts. So we're taking a very value-based approach to these corporate accounts and it's working.

Our next question comes from Michael Ryskin with Bank of America.

Great. I'll ask one big one on Zenrelia and then maybe a quick follow-up. So on the one hand, you're doing much better than any of us had anticipated given the label restrictions. You touched on blockbuster trailing 12 months. We're kind of backing into something like $40 million for the quarter, so it continues to ramp nicely despite the label. On the other hand, the FDA label update, I think, is less than what people were expecting. So I just wonder if you could talk about why you're having such success despite the label restrictions? And if you could give an update on — you called out the additional trials, the data generation — just any thoughts on timing when we could get either more updates or see that label change? And then I have a quick follow-up.

Yes. I think I start with the dermatology market, continuing to grow double digit, truly an amazing quarter. We have a special product in Zenrelia. We've got future year demands coming into this year. So we see the potential of this product much greater than we saw it even last quarter. Our expectations are growing and we're seeing it globally. It's all back to efficacy. The product simply works. Relative to the label, we had constructive dialogue with the FDA regarding the data. They've requested a bit more research. We stepped back on the multipronged approach we took, which is: first, we submitted the PCR data. We got a positive improvement in the label. They requested the published booster data. That's what we submitted, and we knew this was a potential expectation. They requested this additional data, and we've already started the trials along the way. We've got good concurrence on the study, and we'll be submitting it by the end of the year, Michael. But given Zenrelia's success that's well beyond our plans, we now have greater expectations for the potential of this product, with additional label improvement in the U.S. really representing just further possible upside. So our guidance has always been, as I said, conservatively assuming no incremental change to the label. With all of this, the most important thing is we're taking share. We're in over 50% of the clinics in the U.S. Our expectations are growing. We have moved to 24/7 manufacturing because we see the future forecast for this product growing, especially as we head into derm season. And again, we've got two million dogs treated, great PV data, and 44 countries internationally now with all labels without restrictions. So we're in a strong place.

And Michael, as Jeff highlighted, right, a reminder: our 2026 guidance and our Investor Day guidance we gave back in December assumes the label is as-is. It did not assume a label change here in 2026. Where we are today, with the current status and timeline, provides potential upside to growth potentially starting in 2027 with a clean label.

Okay. And if I could squeeze in a quick follow-up on price. I think you saw a 2% price in the quarter. But you also, in your prepared remarks, talked about implementing a significant price increase as you mentioned in the past. Could you just talk about prices, how big that was and price assumptions for the rest of the year? Any specifics would be helpful.

Sure. Price in the quarter is right aligned with our expectations for the quarter and for the year. Price in the quarter, as I highlighted, was 2% across the board. That's both on the pet side and the farm side. I'd remind you that pricing can be influenced by customer and product mix for any quarter. But we do expect 2026 pricing to accelerate from where it was in 2025. That, quite honestly, reflects the enhanced value that our best-in-class innovation is bringing and the comprehensive portfolio we're bringing to customers. And I'd remind you that in U.S. Pet Health, we did bring the highest pricing to vet clinics this year. It's been the highest in five years as we continue to price to value. I think you'll see price accelerate as we see continued ramps in Zenrelia and Quattro throughout 2026.

I would add that prices in the industry are holding up strong. Even in U.S. pet, prices held up nicely, even in corporates. The change has been an increased need to spend to hold and capture share. That's a positive. As everyone is selling value, we don't see price impact; we see spend impact, and we have good measures on the return on our spend, which is why we're leaning in on it.

Our next question comes from Umer Raffat with Evercore.

I thought I would focus a bit today on the non-innovation side for a second. Specifically, what I'm seeing is, while there's all this focus on some of the new launches, your cattle business might have hit an all-time high, if I'm not mistaken. And poultry is also at near the best numbers you've ever put up. So could you speak to the broader dynamic in the farm business? I realize herd count is part of it, but I don't think that's all of it. I'm trying to understand the underlying drivers on both sides, and also how sustainable they are as herd counts come back over time?

Very insightful question, Umer, and I agree with you. Last year in 2025, our industry grew 7% and Farm Animal grew 10%, while Pet Health was 5%. Farm Animal has durable undertones. There's a protein revolution going on, and it's playing through in the numbers. You see Tyson's results with the chicken business. We're expecting about 5% growth in U.S. protein. Meat sales are up meaningfully over the last five years, and there's a shift back to protein. As you look at species, yes, there's pressure in beef herd rebuilding, but the benefit carries over to international beef and poultry. Producers are making money, and we serve producers. Dairy is a quieter story that could be second to poultry and benefiting from this protein trend — new SKUs in shakes and yogurts. So there's big investment in dairy; that's where the AHV acquisition plays nicely. Poultry has had consecutive growth and we don't see that slowing. I think the carryover of protein makes for a strong Farm Animal position. We're in leadership positions across medicated feed additives, vaccines and other additives, and we're adding to that portfolio with the AHV acquisition.

Our next question comes from Brandon Vazquez with William Blair.

Congrats on a nice quarter here. There's not too much to pick on. I did want to go back to the U.S. Pet Health number. I can appreciate there was a little bit of noise in the end markets. But I'm curious, is there anything else we should be thinking about on a year-over-year basis as you think of that number, trying to think of the ramp? Why would a business that had Quattro at a pretty low base in Q1 2025 change so much month to month? I think that's part of what a lot of us are trying to understand as we think about the ramp through the rest of the year.

Maybe I'll give you some color. Last year we did have the initial launch of Credelio Quattro, so we had a tough compare, but even in light of that, we still outgrew Quattro versus last year. For the second half, which gives us confidence, we continue to see strong momentum in Quattro and Zenrelia. Think about the clinics and the data on new purchasers; that's going to continue to ramp throughout the year as we see order rates holding strong. We are investing more in DTC behind these brands. Befrena continues to be on pace with our launch expectations and there's a high degree of excitement about that, particularly across the dermatology portfolio. Corporate accounts will continue to ramp throughout the year. We're confident in the second half of 2026 on the U.S. pet side. And again, our guidance does not assume an improvement in vet visits for the year.

Okay. And then as a follow-up on the guidance, there was a comment about generics in the investor deck and competition. How do you guys think about competition when you're putting together guidance? You're in a unique position with a lot of innovative products out there. Is competition baked in as transient headwinds? Is it price, volume? Any details on what's baked into guidance from competition and generics would be helpful.

We assess competition market by market during our quarterly forecasting with a good competitive intelligence group. As Bob highlighted, we've taken a balanced approach. We've been in our third year of growth and delivery, and that same philosophy is carried forward as we look at the rest of the year for U.S. Pet Health or any business, generics included. We feel good about our assumptions for the rest of the year.

Our next question comes from Daniel Clark with Leerink.

Just wanted to ask about how we should think about the progression of clinic penetration for both Zenrelia and Quattro and the share within those clinics as we go through the rest of 2026, especially given the ramp you had for U.S. Pet?

Because we haven't talked much about Quattro, I'll point to a few statistics. It's off to a great start. The momentum is strong. Think about the four key metrics we highlighted at Investor Day: more clinics, increased share within those clinics, puppy starts and a growing market. We've picked up 2,500 new purchasers year-to-date through April. We're in 40% of U.S. clinics with Quattro, and most importantly, we picked up 13 points of share within those clinics to 53%. We're moving to first-line treatment and we're the number one growth company in market share growth. That's the statistic to watch as it demonstrates best medicine. This is the third quarter in a row we're winning the puppy index and Q1 was greater than Q4. The market grew last year. So despite a weather challenge in January and February, we see resiliency. We expect a strong parasiticide season and derm continues to get more clinics and move to first-line treatment. International markets are also strong for Zenrelia given the market shares we've seen. Those would be the key areas to watch.

Got it. Super helpful. I actually wanted to ask on the international dynamics for Zenrelia. What are you seeing in terms of competitive or promotional intensity from other manufacturers that have products on the market? Any change there? And can you size the market growth you're seeing in derm ex-U.S.?

It's an $800 million market internationally and it's growing double digits, even faster than the U.S. Seventy percent of puppy starts are outside the U.S., so positive trends. The EU head-to-head study is playing out in the field with KOL support and you're seeing market shares take off; reaching market leadership in Brazil after one year is a strong proof point. Even with new entrants, the head-to-head data is resonating and we're winning share in Europe. We'll continue to globalize — we're in 44 international countries — and it's about gaining more share and moving to first-line treatment.

Our next question comes from Christopher Schott with JPMorgan.

Congrats on the progress. The no-regret launch approach has clearly paid off. If this outperformance continues, how should we think about Elanco reinvesting potential upside back into the business? Should we still expect continued promotional spend, or do we reach a point where more of the top line upside flows to the bottom line? And second, on the types of pets moving onto Zenrelia given the share gains, can you elaborate on what you're seeing in terms of new starts versus those who may have failed previous treatments?

Chris, I'll take the first one. I'm pleased with Q1 — it's exactly the profile we'd like to see where we exceed expectations and continue to reinvest in innovative products. We're using data to determine investment, and we see high ROI on these investments, so we'll continue to invest. Elanco Ascend is important because it allows us to beat expectations, drive value to the bottom line while also reinvesting. Investment is in two spots: near-term DTC for the brands and continued R&D for the next wave and subsequent wave of innovation.

We hosted a major vet conference last week and dermatology experts had over 300 vets at our headquarters. The buzz is Zenrelia efficacy and movement to first-line treatment. We began with acute and seasonal cases and are seeing a shift to more chronic cases, which represent two-thirds of the derm patient population and where volume is larger. Befrena adds to the portfolio with a differentiating 6- to 8-week dosing claim, and it complements Zenrelia. With these two differentiated assets and a growing derm market, Elanco becomes a very competitive derm player. The news this quarter is Zenrelia's momentum and Befrena coming into the market, with Quattro supporting parasiticide and derm overlaps.

Our next question comes from Steven Dechert with KeyBanc.

Just wanted to touch on your expectations for visit volumes. It sounded like in March you saw a big improvement and April continued. How are you thinking about the rest of the year with what might be a more constrained consumer budget? I understand you're not baking this into your guidance, but what is your outlook?

We monitor vet visits closely. Non-wellness visits went up. We think visit volumes are not a determinant of our success in 2026, and we don't see veterinary visit trends as a short-term or long-term limiting factor. Expectations of care are driving a willingness to spend. Innovation and portfolio matter, and convenience matters; we're the leader in omnichannel and global reach. Our relationship with distribution gives us a share-of-voice advantage. Those trends are more important than vet visit counts for our outlook.

Great. One more on Befrena: any key milestones to look for over the next few quarters? And any more color on the feedback you've received to date?

Befrena is a ramped launch common for monoclonal antibodies. We're in it now with KOLs and influencers. We'll start to move into the marketplace this quarter, and it will ramp in a staged way into the second half and be a contributor to U.S. Pet Health growth. We also have a submission into Canada. It will be a major player into 2027 as we scale manufacturing and distribution.

Our next question comes from Navann Ty with BNP Paribas.

One on Befrena: if you can expand on strategy, especially as a competitor is launching a long-acting product likely in early 2027. Interested to hear if you take a similar approach to Zenrelia. And in Farm Animal, you touched on herd regrowth. Can you discuss your outlook for medicated feed additives in particular?

We have our second dermatology product with momentum and differentiation on efficacy, convenience and value. We start Befrena in a large market with many seasonal and acute cases, so it fits well. We also have next-generation derm, including long-acting products in our pipeline, so we're well suited to grow derm leadership through the decade. For medicated feed additives, durable trends continue. We point to our portfolio of Experior, Rumensin and other key products — and in poultry we are a market leader — and we continue to hold and grow share globally.

And our last question comes from Daniel Grosslight with Citi.

Congrats on the quarter. I wanted to ask about capital deployment priorities now that it seems you'll hit leverage targets earlier than anticipated. How are you thinking about M&A? Does this open the aperture for larger deals, and what areas would you look at? Also, similar question on buybacks: when would you feel comfortable turning on buybacks as leverage comes under the 3x target?

As I think about capital allocation, no change to the strategy we've laid out. Organically investing in the business and paying down debt remains our number one priority. We will continue to look at M&A, but these will be small tuck-under opportunities and won't derail our deleveraging timeline to get to 3 to 3.2x at the end of this year and below 3 in 2027. As we get below 3 in 2027, that gives us more flexibility with capital deployment and shareholder return. We haven't been explicit on what that looks like yet; we'll continue to work with the Board and be transparent with the Street as we have more clarity.

Yes, I was going to ask another question on the ramp-up with new deals with Costco and Dollar General on the retail side. How should we think about the revenue and margin impact of these new partnerships as they ramp in 2026 and scale in 2027 and beyond?

Think of these customers as seasonal buying patterns, particularly for the Advantage brand where we saw strength with Costco and Dollar General. You'll see a first half purchasing dynamic with reorder rates through the first half. Because it's seasonal, inventory will deplete over these customers in the second half, but we'd expect reorders again in 2027. So think of this as a seasonal first-half opportunity for us.

Thank you for your time, everybody, this morning and continued interest in Elanco. This is one of our best quarters since the IPO: high-quality growth, a base business that grew in Q1, and a basket of significant innovation building momentum on a durable animal health industry. Momentum is evident in market share gains across our portfolio. The IPP strategy is working. Engagement at Elanco is very high. We're a different company today, well positioned to lead animal health. We'll keep our focus on growth, innovation and cash. We appreciate the interest in Elanco and will remain focused on delivering value for customers, communities and shareholders. Thank you for your time today. We look forward to engaging through the quarter. Have a great day.

Thank you. This concludes the program. You may now disconnect.